Volv Global expands the boundaries of medical understanding and boosts awareness of difficult-to-diagnose diseases among physicians and key opinion leaders with credible real-world data insights for better clinical decision-making.
Detect novel biomarker sets for more complete understanding of disease and faster diagnosis of difficult-to-diagnose patients.
Use advanced machine learning techniques to overcome issues of longitudinality, unstructured data, data sparsity and bias in data sources.
Identify cohorts more precisely and at an early stage for better longitudinal assessment of patient health outcomes.
Understand disease progression better to diagnose patients showing early signs or triage those with rapidly progression.
Medical affairs in the face of complexity
Limited understanding of underexplored disease areas or newly identified phenotypes.
Rapid advancements in disease understanding create challenges in conveying evolving disease knowledge to healthcare professionals.
Challenge in generating real-world evidence (RWE) for understanding of diseases, esp. for rare diseases or newly emerging conditions.
Variability in disease presentation across diverse patient populations.
Identifying and characterising rare adverse events or long-term outcomes.
Supporting Clinical Development
We find undiagnosed and misdiagnosed patients, expanding the pool of patients for clinical trial recruitment.
We find patients before the development of traditional symptoms, before they are given conventional therapies.
We enable triage of patients according to prognosis of outcomes, e.g., fast progressors, or progressors to more acute symptoms.
We differentiate and cluster heterogeneous patient cohorts for more accurate definition of trial inclusion and exclusion criteria.
Leading AI/ML methodology to support Medical Affairs
Medical affairs teams benefit from inTrigue’s ability to reveal crucial patient indicators and predict treatment response, drawing on advanced AI and machine learning. By identifying subtle disease biomarkers, phenotypes, or other clinical features, inTrigue ensures no patient is overlooked—informing scientific exchange and shaping evidence-based recommendations. Coupled with real-world insights on disease progression, medical affairs professionals can guide healthcare providers in selecting the most effective interventions, reinforcing patient-centric care across diverse populations.
Shaping the future today
Machine learning applied to 3,549 confirmed Pompe disease patients – the largest machine learning study of the diseas...
New research demonstrates that machine learning can map clinician-defined endpoints to real-world claims data in Pomp...
Explore Volv Global’s ISPOR 2026 research with Sanofi on Pompe disease, based on use of machine learning-driven endpo...
Repeated steroid use in IBD care signals failing treatment pathways. Learn why steroid exposure is a key red flag and...
Discover how patient advocacy accelerates rare disease diagnosis and innovation, bringing technology, real-world data...
Explore why diagnostic delays in cancer remain a major challenge and how earlier diagnosis, better data, and healthca...
Discover how data-driven insights help identify undiagnosed rare disease patients earlier and close the diagnostic ga...
Explore a podcast on rare disease diagnosis, diagnostic delays, and how AI innovation can shorten the path from sympt...
Chronic Obstructive Pulmonary Disease remains under-recognised & under-diagnosed. How do we ensure COPD patients ...
MASH/NASH: Why Therapeutic Breakthroughs Demand a New Era of Patient Identification. Novel therapies only achieve the...
Bridging gaps across the CLL care pathway, Part 2: Knowing When To Treat – AI for Transformation, Infection Risk, and...
Bridging gaps across the CLL care pathway, Part 1: From Signal to Stratification – Reimagining Early CLL Care through...
